Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results

NEXT STORY
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
PREV STORY
Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results

HOPKINTON, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a ...

author_avatar
NASDAQ Market News

Global Human Vaccines Market 2015-2025 | by Disease, End-user & Leading Vaccine with Profiles on Key & Emerging Players

author_avatar
NASDAQ Market News

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

author_avatar
NASDAQ Market News